Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421286 | 0.84 | SYK (0.61) | SYKSMN1; SMN2LMNAMAPTIDO1 | |
| SCHEMBL15202883 | 0.83 | SYK (0.64) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL19972926 | 0.83 | SYK (0.64) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL26291271 | 0.83 | SMN1; SMN2 (0.55) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL15584494 | 0.83 | HTT (0.54) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL18002248 | 0.83 | SMN1; SMN2 (0.58) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL31489054 | 0.82 | SMN1; SMN2 (0.54) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL24073139 | 0.82 | SYK (0.54) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL756175 | 0.81 | SYK (0.56) | SYKSMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL27190527 | 0.81 | SMN1; SMN2 (0.57) | SYKSMN1; SMN2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590982-B1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) | 2017-08-23 | — | — | EP | disclosed |
| EP-2590982-B1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) | 2017-08-23 | — | — | EP | disclosed |
| US-8962830-B2 | Protein kinase inhibitors and methods of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-24 | — | — | US | disclosed |
| US-8962830-B2 | Protein kinase inhibitors and methods of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-24 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| EP-2590982-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | The Walter and Eliza Hall Institute of Medical Research (AU) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003544-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012003544-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | PRKDC, PRKACA, PRKX | SYK 675/4885SMN1; SMN2 3891/4885LMNA 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.